期刊文献+

液相色谱-四极杆飞行时间质谱联用法鉴定注射用盐酸吉西他滨中的未知杂质 被引量:1

Identification of Major Impurity in Gemcitabine Hydrochloride for Injection by HPLC-QTOF
原文传递
导出
摘要 目的对注射用盐酸吉西他滨的主要杂质进行结构分析。方法采用液相色谱-四级杆飞行时间质谱联用技术对该杂质进行结构分析,色谱条件:采用ZORBAX Eclipse XDB-C18(4.6 mm×250 mm,5μm)色谱柱,以甲醇-10 mmol·L-1醋酸铵溶液(用醋酸调节pH至5.7))(1∶9)为流动相,流速1.0 mL·min-1;质谱条件:正离子检测模式,毛细管电压:4.0 kV,锥孔电压:65 V,喷雾气压:310 kPa,干燥气(氮气)流量:11 L·min-1,干燥气温度:350℃,碎裂电压150 V;结吉西他滨与该杂质的多级质谱裂解规律,研究质谱碎片裂解途径,鉴定该杂质的结构。。结果该未知杂质为2'-脱氧-2',2'-二氟尿苷。结论本实验为药物的杂质控制和工艺优化提供参数,进而提高用药安全性。 OBJECTIVE To elucidate the structure of the major impurity in gemcitahine hydrochloride for injection. METHODS HPLC-QTOF-MS was adopted to analyze the structure of this impurity based on the fragmentation behavior of gemcitabine and this impurity. The separation was performed on a ZORBAX Eclipse XDB-C18 (4. 6mm×250mm,5μm) column. A mixture of 10% meth- anol and 90% 10 mmol·L^-1 ammonium acetate(pH 5.7) was used as mobile phase. Flow rate was 1.0 mL · min ^-1. MS was per- formed under positive mode with 4. 0 kV capillary voltage, 65 V skimmer, 310 kPa spray pressure, 11 L · min ^-1 drying gas (nitrogen) flow rate, 350 %2 drying gas temperature and 150 V fragmentor. CONCLUSION This study offers scientific data for studying the ori- gin of the imt)urity of gemcitabine hydrochloride and improving its quality.
出处 《中国药学杂志》 CAS CSCD 北大核心 2013年第9期739-742,共4页 Chinese Pharmaceutical Journal
关键词 注射用盐酸吉西他滨 杂质结构 高效液相色谱法 高分辨质谱 gemeitabine hydroehloride for injection impurity structure HPLC high resolution MS
  • 相关文献

参考文献6

二级参考文献35

  • 1叶萍,李兆申,张文俊,刘枫,施新岗.吉西他滨肝动脉灌注治疗晚期肝癌[J].第二军医大学学报,2006,27(10):1154-1156. 被引量:10
  • 2霍伟,曲范杰,范丽昕,张咏梅,李萍.吉西他滨联合卡铂一线治疗晚期非小细胞肺癌疗效观察[J].临床肿瘤学杂志,2006,11(11):828-829. 被引量:14
  • 3LINBing—cheng(林炳承).2ndEd(第二版),IntroductionofCapillaryElectrophoresis(毛细管电泳导论),Beijing(北京)[M].Science Press(科学出版社),1996,1..
  • 4LICHTMAN S M, VILLANI G. Chemotherapy in the elderlysp- harmacologic considerations [ J ]. Cancer Control, 2000,7 ( 6 ) : 548-556.
  • 5LARRY W H, GEORGE B B, STAN J, et al. Evaluation of the antitumor activity of gemcitabine [ J ]. Cancer Res, 1990, 50 (14) :4417-4422.
  • 6SCHILLER JII. Future directions in non-small-cell lung cancer [J]. Semin Oncol,1999,26(2 suppl 7):120-124.
  • 7FOGLI S, DANESI F, BRAUD DE, et al. Drug distribution and pharmacokinetic/phannacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer [ J]. Ann Oncol,2001,12 ( 11 ) : 1553-1559.
  • 8PEREZ-MANGA G, LLUCH A, ALBA E, et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase Ⅱ pharmacokinetic trial [ J ]. J Clin Oncol, 2000,18 ( 13 ) :2545-2552.
  • 9KIANI A, KOHNE C H, FRANZ T, et al. Parmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment [ J ]. Cancer Chemother Pharmacol, 2003,51 ( 3 ) : 266 - 270.
  • 10IAFFAIOLI R V,TORTORIELLO A,GAE-TANO F,et al. Phase Ⅰ - Ⅱ study of gemcitabine and carboplatin in stage Ⅲ B-Ⅳ non- small-cell lung cancer[J]. J Clin Oncol,1999(3) :921-931.

共引文献47

同被引文献11

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部